Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 20/20 | 0.77 |
| ▸ | CDK8 | P49336 | 20/20 | 0.77 |
| ▸ | CDK19 | Q9BWU1 | 4/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14874499 | 1.00 | CCNC (0.77) | CCNCCDK8CDK19 | |
| SCHEMBL18491384 | 0.91 | CCNC (0.87) | CCNCCDK8CDK19 | |
| SCHEMBL18491382 | 0.91 | CCNC (0.87) | CCNCCDK8CDK19 | |
| SCHEMBL21506417 | 0.89 | CCNC (0.75) | CCNCCDK8CDK19 | |
| SCHEMBL19241777 | 0.88 | CCNC (0.78) | CCNCCDK8CDK19 | |
| SCHEMBL19241905 | 0.88 | CCNC (0.77) | CCNCCDK8CDK19 | |
| SCHEMBL18491858 | 0.87 | CCNC (1.00) | CCNCCDK8CDK19 | |
| SCHEMBL18491860 | 0.87 | CCNC (1.00) | CCNCCDK8CDK19 | |
| SCHEMBL18491439 | 0.86 | CCNC (0.79) | CCNCCDK8CDK19 | |
| SCHEMBL18491442 | 0.86 | CCNC (0.79) | CCNCCDK8CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937055-B2 | Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-20 | — | — | US | disclosed |
| US-8937055-B2 | Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20130296276-A2 | HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296276-A2 | HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130116214-A1 | HETEROCYCLIC RING COMPOUND | UJIKAWA OSAMU (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116214-A1 | HETEROCYCLIC RING COMPOUND | UJIKAWA OSAMU (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2583965-A1 | HETEROCYCLIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-04-24 | — | — | EP | disclosed |
| EP-2583965-A1 | HETEROCYCLIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116214-A1 | HETEROCYCLIC RING COMPOUND | FABP4, CPT1B, GPR119 | CCNC 2799/4885CDK8 3684/4885CDK19 4017/4885 |
| US-20130296276-A2 | HETEROCYCLIC RING COMPOUND | FABP4, CPT1B, GPR119 | CCNC 2799/4885CDK8 3684/4885CDK19 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.